Incannex Healthcare Inc.

What they do

Incannex develops oral fixed-dose combination and psilocybin-based therapies. Lead candidates are IHL-42X (dronabinol and acetazolamide) in a pivotal Phase 2/3 trial for obstructive sleep apnea, PSX-001 (synthetic psilocybin plus psychotherapy) in Phase 2 development for generalized anxiety disorder, and IHL-675A (CBD and hydroxychloroquine sulfate) for inflammatory conditions initially rheumatoid arthritis. The company is not yet commercializing any drug and has no approved products.

Revenue drivers

• No marketed products — Incannex has no approved drugs and generates negligible revenue, with reported annual revenue of $12,000 in fiscal 2024 and $86,000 in fiscal 2025.
• IHL-42X (obstructive sleep apnea) — The lead clinical program; no revenue today and value depends on future Phase 3 success and regulatory approval.
• PSX-001 (generalized anxiety disorder) — Phase 2-stage psilocybin candidate; no revenue today and a multi-jurisdiction Phase 2 trial is planned for 2026.
• IHL-675A (inflammatory conditions/rheumatoid arthritis) — Early-stage candidate; the Australian Phase 2 trial was terminated due to recruitment challenges, and the company is planning a U.S. IND-opening study.

Recent performance

Revenue remains minimal, at $12,000 in fiscal 2024 and $86,000 in fiscal 2025. Annual net loss was $48.8 million in 2023, $18.5 million in 2024, and $46.9 million in 2025. Diluted EPS was $2.76 in 2022, -$3.32 and $0.38 in 2023, -$1.15 in 2024, and -$1.35 in 2025. Operating cash use was $10.7 million in 2023, $15.8 million in 2024, and $12.5 million in 2025. The most recent quarters reported revenue of $74,000 in the quarter ended September 30, 2024 and $12,000 in the quarter ended December 31, 2024.

Strategy

Incannex is prioritizing its clinical pipeline, led by IHL-42X for obstructive sleep apnea, for which it is finalizing an End of Phase meeting with the FDA to obtain guidance on a pivotal Phase 3 trial design. The company reported positive Phase 2 RePOSA data for IHL-42X, including up to 83% reduction in AHI in the high-dose group, and is preparing a multi-jurisdiction Phase 2 trial of PSX-001 in generalized anxiety disorder in 2026. For IHL-675A, after terminating the Australian Phase 2 trial due to recruitment challenges, the company is developing a strategy for a U.S. IND-opening study in rheumatoid arthritis. The strategy relies on internal development of novel therapies for serious chronic conditions with limited treatment options.

Risks

• History of operating losses — Incannex has reported net losses each year, including $46.9 million in fiscal 2025, and may not achieve profitability without successful drug development.
• Need for substantial additional funding — The company expects to need substantial additional capital to continue developing its drug candidates and could be forced to delay or eliminate programs if unable to raise funds on favorable terms.
• Regulatory and clinical trial risk — None of Incannex's drug candidates are approved, and the IHL-42X pivotal program and PSX-001 and IHL-675A studies remain subject to FDA and other regulatory outcomes.
• Nasdaq listing and R&D tax incentives — Incannex may be unable to maintain its Nasdaq Capital Market listing, and its operations rely on R&D tax incentives that could decrease.

Outlook

Management's stated near-term focus is obtaining FDA guidance on the IHL-42X Phase 3 design after the End of Phase meeting and initiating a multi-jurisdiction Phase 2 trial of PSX-001 in generalized anxiety disorder in 2026. The company also plans to develop a U.S. IND-opening study for IHL-675A in rheumatoid arthritis. No revenue guidance or commercial launch is provided, and the company expects to need substantial additional funding.